Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 13/20 | 0.38 |
| ▸ | CA9 | Q16790 | 8/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30437398 | 0.91 | CA2 (0.47) | CA2TP53CA1CA9CA12 | |
| SCHEMBL15562345 | 0.78 | CA2 (0.42) | CA2TP53CA1CA9CA12 | |
| SCHEMBL27675605 | 0.76 | TP53 (0.43) | CA2TP53CA1 | |
| SCHEMBL28229721 | 0.76 | FAAH (0.39) | CA2TP53CA1 | |
| SCHEMBL1415215 | 0.76 | TP53 (0.34) | CA2TP53CA1CA12CA14 | |
| SCHEMBL8715933 | 0.75 | CA2 (0.43) | CA2TP53CA1CA9CA12 | |
| SCHEMBL15620908 | 0.74 | — | — | |
| SCHEMBL222613 | 0.73 | TP53 (0.50) | CA2TP53CA1CA9CA12 | |
| SCHEMBL2185910 | 0.73 | TP53 (0.45) | CA2TP53CA1CA9CA12 | |
| SCHEMBL276801 | 0.71 | CA2 (0.43) | CA2TP53CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108598-B | Thiazoles as Ror gamma t modulators | 詹森药业有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3212642-B1 | AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORGAMMAT | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3212641-B1 | THIAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10080744-B2 | Thiazoles as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-25 | — | — | US | disclosed |
| CN-108064224-A | Amide-substituted thiazoles as modulators of Ror gamma t | 詹森药业有限公司 | 2018-05-22 | — | — | CN | disclosed |
| US-20180064690-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-9861618-B2 | Thiazoles as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-09 | — | — | US | disclosed |
| US-9845319-B2 | Amide substituted thiazoles as modulators of RORyt | Janssen Pharmaceutiuca NV (BE) | 2017-12-19 | — | — | US | disclosed |
| EP-3212641-A1 | THIAZOLES AS MODULATORS OF RORyt | Janssen Pharmaceutica NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| EP-3212642-A1 | AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORyT | Janssen Pharmaceutica NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1751139-B1 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2295426-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295427-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7838524-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| EP-1751139-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | UMPS, SLC14A1, TP53 | CA2 3611/4885TP53 3/4885CA1 3721/4885 |
| US-10080744-B2 | Thiazoles as modulators of RORγt | RORB, RORA, RORC | CA2 3582/4885TP53 2673/4885CA1 3568/4885 |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | UMPS, SLC14A1, TP53 | CA2 3611/4885TP53 3/4885CA1 3721/4885 |
| US-20180064690-A1 | THIAZOLES AS MODULATORS OF RORyt | RORC, RORB, RORA | CA2 2968/4885TP53 2552/4885CA1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.